This content was created by Everyday Health Media on behalf of an advertiser.
More Information.
Content on this page was created by the Everyday Health Media team and is funded by an advertiser. The content conforms to Everyday Health Media’s editorial standards for accuracy, objectivity, and balance. The advertiser may select the specialty area but does not edit or approve the content.
Advances in Paroxysmal Nocturnal Hemoglobinuria
PNH Treatment: A New Era
New agents in development for paroxysmal nocturnal hemoglobinuria are showing promising results, both by reducing residual symptoms of the disease as well as by lessening the burden associated with the treatment itself.
Predicting Stent Thrombosis: Who Needs PNH Screening?
Researchers in the U.K. took a critical look at systemic hematological manifestations and stent thrombosis, including an interesting case presentation of ST in a man with previously undiagnosed paroxysmal nocturnal hemoglobinuria.
COVID-19 Vaccine Response in Patients with PNH or Aplastic Anemia
There’s concern that patients with paroxysmal nocturnal hemoglobinuria or aplastic anemia may have an increased risk of more-severe SARS-CoV-2 infections. How did these populations do after being vaccinated?
Pediatric Cancer and Bone Marrow Failure Implicated in Poor Psychosocial Outcomes
Young patients who survive cancer or an inherited disorder that requires hematopoietic stem cell transplantation face challenges unlike those of other pediatric cancer survivors. This calls for a new approach to rehabilitation, say the authors of a recent study.
In PNH, What Drives Progression to Secondary Myeloid Neoplasms?
A large retrospective analysis of malignant evolution in patients with aplastic anemia and paroxysmal nocturnal hemoglobinuria has identified morphological, cytogenetic, and molecular high-risk features for secondary myeloid neoplasms.
The Persistent Toll of Paroxysmal Nocturnal Hemoglobinuria
Most patients with paroxysmal nocturnal hemoglobinuria who have been treated with at least 1 year of C5 inhibitor therapy still have hemoglobin levels below 12.0 g/dL. Continued fatigue and other symptoms related to this anemia were reported in this study.
PNH Clone Characteristics: A Variety Show
The authors developed a new flow cytometry assay to determine the characteristics of paroxysmal nocturnal hemoglobinuria clones in white blood cells. Patients had different PNH abnormalities in different cell types.